Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating KarXT for manic episodes in Bipolar I disorder is recruiting. The study is sponsored by Bristol-Myers Squibb.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Bipolar-I Disorder With Mania or Mania With Mixed Features | Phase 3 | Status: RECRUITING